We updated our FY24 visitor numbers after Canadian peer Cineplex disclosed that recent Hollywood tentpoles like Moana 2 and Wicked fuelled blockbuster box office performance in December 2024 but less than we thought. The Canadian exhibition giant also cautioned Thanksgiving holdovers and more year-end titles left Cineplex still below pre-pandemic box office revenue in Dec-2019. If we extrapolate this (combined with recent Box Office Mojo data for US box office data for 4Q24) we now bank on 33.3m...
Yesterday a second extraordinary general meeting (EGM) of Gimv took place following the no-quorum meeting of 23-Dec-2024 and Gimv's shareholders approved Gimv's strategic growth ambitions and gave the go-ahead for a possible capital increase. We note that Gimv will be hosting a CMD on 22-Jan-2025 during which, management will provide more details about its new strategy and the potential capital raise. Post capital raise, Gimv aims to double its portfolio size while helping grow some of its top i...
Yesterday before US market opens, Autolus provided a business update and an overview of 2025 milestones, where the US commercial launch of Aucatzyl in r/r ALL is progressing in line with previously guided timelines. With 24 centres already authorised (targeting 30 by end Jan'25), the first commercial sales of Aucatzyl could come anytime now. We believe initial positive experience with the product will be key to drive adoption in FY25, and Autolus' manufacturing process has been stress tested to ...
Smartphoto group announced the acquisition of System Insight Holdings, a UK company specialized in event and souvenir photography under the commercial name Image Insight. With this acquisition, Smartphoto adds a new component to its growing B2B division. This acquisition will join Smartphoto's B2B division alongside TopFanZ, a previously acquired company specializing in fan merchandise in the sports and entertainment sector. Event and attraction photography is a growing market worldwide, driven ...
Biotalys provided an update on its regulatory review procedure for Evoca in Europe, where the Dutch authority Ctgb has now issued a positive draft assessment report, recommending the approval of Evoca's active ingredient throughout the EU. The draft report follows the earlier decision to allow large-scale demonstration trials with human consumption, and marks an important milestone in the regulatory review. The procedure will now be further followed up by EFSA with Biotalys anticipating full app...
Autolus Therapeutics Provides Business Updates and 2025 Overview - Ongoing commercial launch of AUCATZYL® on track, with 24 treatment centers fully authorized as of January 10th - National Comprehensive Cancer Network® adds AUCATZYL® to its Clinical Practice Guidelines in Oncology (NCCN Guidelines®) - Company to provide clinical development program updates, including plans for expansion into autoimmune disease, at April 23rd R&D investor event LONDON, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a commercial stage biopharmaceutical company developing, man...
mdxhealth provides insight into key FY24 parameters, with revenues landing at $ 90m (KBCSe: $ 88.5m) and YE cash at $ 46.8m (KBCSe: $ 47.1m. Revenue guidance for FY25 is set at a narrow yet ambitious range of $ 108-110m, implying a 20-22% y/y increase. We believe that mdxhealth is well-positioned for growth in 2025 now that the commercial engine is firing on all cylinders, hence we maintain our $ 4.2 TP and Buy rating.
MDxHealth Reports Preliminary Fourth Quarter and Full Year 2024 Revenues and Issues 2025 Revenue Guidance MDxHealth Reports Preliminary Fourth Quarter and Full Year 2024 Revenues and Issues 2025 Revenue Guidance IRVINE, CA – January 13, 2025 () – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leading precision diagnostics company, today reported preliminary fourth quarter and full year 2024 revenues and issued 2025 revenue guidance. The Company expects to report fourth quarter and full year 2024 revenues of approximately $24.7 and $90.0 million, respectively, ...
We are hosting our 28th ODDO BHF Forum in Lyon on 9 and 10 January 2025. In total, 211 companies will be presenting over the two days. In the following note, we provide some initial feedback from the companies on day 1. Out of the 104 feedbacks collected during the first day, 40 were clearly positive, 59 rather Neutral, and only 6 negative. Among the positive names, we would particularly highlight Accor, URW, Euronext, Bureau Veritas, Renke, ID Logistics, Roche Bobois, Ionos, Companie des Alpes...
1M Performance - Absolute: During Dec'24 (1M period), the KBCS Holdings Universe posted a return of -3.2% which was mainly driven by multi-asset holdings (-4.3%) while single-asset holdings posted a significantly less negative return of -0.6%. The 3 top performers during the period were D'Ieteren Group (+26.6%), Compagnie du Bois Sauvage (+7.0%) and KBC Ancora (+7.0%) while the 3 worst performers were Exor (-5.4%), Heineken Holding (-3.6%) and Gimv (-1.1%). FY24 Performance - Relative: During ...
Gimv announced that it has sold its majority stake in KÖBERL Group (facility management and building technology services) to Hungarian company B+N Referencia Zrt. The transaction is anticipated to have a positive impact of approximately €1.0 on Gimv's NAVps and the return on this investment has significantly exceeded Gimv's long-term portfolio return target of 15.0%. This is the third transaction that Gimv has complete post its 1H results. We see this as an indication of the superior quality of ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.